Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico
Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico is recorded as a service provider in 2 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 2 of 2 trials · Latest update first
A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with standard of care in participants with platinum- resistant ovarian cancer.
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with chemotherapy in participants with endometrial cancer after platinum-based chemotherapy and immunotherapy
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico?
The 2026-10-09 snapshot links Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico to 2 distinct CTIS trials. Recorded services include Collaborative Group (Research Network), Research network. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico?
The most frequently recorded therapeutic areas are Gynecology, Solid Tumor Oncology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico conducted?
The linked trials record locations in 15 countries, including Belgium, Czechia, Germany, Denmark, Spain. These are trial locations, not confirmed office locations or countries where Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico delivered services.
What can this page tell me about Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico's trial experience?
Browse 2 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico